Arcellx, INC 8-K filings

Arcellx, Inc. has been acquired by Gilead Sciences, Inc. for approximately $7.1 billion, marking the completion of a tender offer and subsequent merger.

Gilead Sciences will acquire Arcellx for an implied equity value of $7.8 billion, including a $115 cash per share and a $5 contingent value right, to gain full control of the promising anito-cel CAR T-cell therapy for multiple myeloma.

Arcellx announced new positive data from its pivotal Phase 2 iMMagine-1 study for anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma, demonstrating high response rates and a manageable safety profile.

Arcellx, Inc. announced its third quarter 2025 financial results, reporting a significant decrease in collaboration revenue and an increased net loss compared to the prior year.

Arcellx announced positive Phase 2 iMMagine-1 study data for anito-cel in RRMM, FDA clearance for ACLX-004 IND, and Q2 2025 financial results with cash runway into 2028.

Arcellx, Inc. announced the successful outcomes of its Annual Meeting of Stockholders held on May 28, 2025, with all proposed matters, including director elections, executive compensation, and auditor ratification, receiving strong shareholder approval.

Arcellx reports promising results from its Phase 2 iMMagine-1 study of anito-cel, demonstrating high overall response rates and manageable safety in patients with relapsed or refractory multiple myeloma.

Arcellx announces its Q1 2025 financial results, highlighting clinical advancements, board appointments, and a strong cash position to fund operations into 2028.

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors, adding financial and healthcare leadership as Derek Yoon steps down.

Arcellx reports positive clinical data for anito-cel in relapsed or refractory multiple myeloma and highlights a strong cash position extending into 2027.

Arcellx announced promising results from its Phase 2 iMMagine-1 study of anito-cel, a CAR T-cell therapy for relapsed or refractory multiple myeloma, at the American Society of Hematology Annual Meeting.

Arcellx reported highly positive preliminary results from its Phase 2 iMMagine-1 study of anito-cel, demonstrating a 97% overall response rate and a 62% complete response rate in patients with relapsed or refractory multiple myeloma.

Arcellx reports positive clinical trial results for its anito-cel therapy in multiple myeloma, along with third quarter financial results showing increased collaboration revenue and reduced R&D expenses.

Arcellx reported highly encouraging clinical data for its anito-cel therapy in relapsed or refractory multiple myeloma, including a 95% overall response rate in a Phase 2 study, and announced the first patient dosed in the iMMagine-3 study.

Arcellx reported its Q2 2024 financial results, highlighted by a $68 million milestone payment from Kite and progress in its clinical programs.

Arcellx, Inc. successfully held its annual meeting, re-electing three Class II directors and approving executive compensation matters.

Arcellx reported a net loss of $7.2 million for the first quarter of 2024, an improvement from a $27.3 million loss in the same period last year, driven by increased collaboration revenue.

Arcellx Inc. has dismissed Ernst & Young as their independent auditor and appointed PricewaterhouseCoopers, effective March 8, 2024.

Arcellx announced its 2023 financial results, highlighted by a $200 million investment from Kite Pharma, robust clinical data for anito-cel, and a cash runway extended into 2027.

Arcellx Inc. has terminated its Gaithersburg, MD lease and officially moved its headquarters to its existing office space in Redwood City, CA, effective January 30, 2024.